Insulet Corp (NASDAQ: PODD)

Insulet Corporation develops manufactures and sells proprietary continuous insulin delivery systems for people with insulin dependent diabetes. Its Omnipod platform comprises the Omnipod 5 Automated Insulin Delivery System the Omnipod DASH Insulin Management System and the original Omnipod Insulin Management System. The Omnipod 5 system features a tubeless pod that houses a cannula for insulin delivery and contains an embedded algorithm that communicates with a Bluetooth linked continuous glucose monitor to adjust dosing automatically. The Omnipod DASH system uses a tubeless pod controlled by a handheld personal diabetes manager with a color touch screen and offers wireless data uploads via WiFi in the United States. Both systems are waterproof with an IP28 rating allowing wear while swimming showering or exercising and can be placed on the abdomen, hip, back of upper arm, upper thigh, or lower back. In addition the company manufactures insulin delivery pods for Amgen to be used in the Neulasta Onpro kit.

The company generates revenue primarily from the sale of its Omnipod pods, controllers and related accessories to wholesalers, distributors and directly to consumers in the United States and internationally. It also earns revenue from producing pods for Amgen under a supply agreement that supplies the Neulasta Onpro kit. Sales are driven by demand for tubeless insulin delivery that integrates with continuous glucose monitors and automated insulin dosing algorithms which improve glucose time in range and reduce the burden of multiple daily injections. For the year ended December 31 2024 approximately 88% of Omnipod product sales globally were made through intermediaries while the remaining share came from direct to consumer channels. The largest customers by revenue share are Distributor A, Distributor B and Distributor C which accounted for 28%, 26% and 21% of total revenue respectively in 2024.

Insulet competes in the insulin delivery market against traditional tubed pump manufacturers such as Medtronic MiniMed and Tandem Diabetes Care as well as suppliers of multiple daily injection therapies. Its competitive advantage stems from the tubeless waterproof pod design that simplifies wearability and eliminates tubing related inconvenience. The company further differentiates itself through integration with third party continuous glucose monitors and proprietary automated insulin algorithms that aim to improve glucose time in range and reduce hypoglycemic events. Insulet estimates that approximately 5,000,000 people have type 1 diabetes and 6,000,000 have insulin intensive type 2 diabetes in the countries it serves while another 3,000,000 people with type 2 diabetes in the United States require only basal insulin. Research and development efforts focus on enhancing the Omnipod 5 algorithm, expanding sensor compatibility, and conducting feasibility trials such as the EVOLUTION study in New Zealand to test usability improvements for both type 1 and type 2 patients. The company maintains a robust intellectual property portfolio with over 750 issued patents and more than 550 pending applications covering pod design, drive systems, cannula insertion, software algorithms and future generation concepts.

Insulet serves individuals with insulin dependent diabetes including those with type 1 diabetes and insulin requiring type 2 diabetes. Its customers also comprise healthcare providers who prescribe the system, payors who reimburse the therapy, and distributors that bring the product to pharmacies and retail channels. The company sells its products in 25 countries across Europe the Middle East Asia and North America. Among its largest customers are Distributor A, Distributor B and Distributor C which together accounted for a majority of total revenue in recent periods.